Which regimen is effective in treating r/rDLBCL in patients ineligible for allogeneic stem cell transplantation (ASCT)?

Updated: Aug 20, 2020
  • Author: Shipra Gandhi, MBBS; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Polatuzumab vedotin-piiq, an antibody-drug conjugate targeting CD79b, has shown significantly improved outcomes for relapsed or refractory DLBCL in patients ineligible for allogeneic stem cell transplantation (ASCT) when combined with bendamustine and rituximab (BR) compared with BR alone. [80] In 2019, the US Food and Drug Administration (FDA) granted accelerated approval to polatuzumab vedotin-piiq, in combination with bendamustine and a rituximab product, for treatment of adult patients with relapsed or refractory DLBCL, after at least two prior therapies. [81]

Selinexor is the first oral selective inhibitor of nuclear export (SINE) compound. In June 2020, the FDA granted selinexor accelerated approval for relapsed or refractory DLBCL, including DLBCL arising from follicular lymphoma, in patients previously treated with at least 2 lines of systemic therapy. [82]

Tafasitamab, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, is approved, in combination with lenalidomide, for the treatment of adults with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are ineligible for autologous stem cell transplant (ASCT). 

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!